These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC; Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660 [TBL] [Abstract][Full Text] [Related]
45. Baricitinib in Patients with Refractory Rheumatoid Arthritis. Genovese MC; Kremer J; Zamani O; Ludivico C; Krogulec M; Xie L; Beattie SD; Koch AE; Cardillo TE; Rooney TP; Macias WL; de Bono S; Schlichting DE; Smolen JS N Engl J Med; 2016 Mar; 374(13):1243-52. PubMed ID: 27028914 [TBL] [Abstract][Full Text] [Related]
46. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial. Kjørholt KE; Sundlisæter NP; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Kvien TK; Solomon DH; van der Heijde D; Haavardsholm EA; Lillegraven S Lancet Rheumatol; 2024 May; 6(5):e268-e278. PubMed ID: 38583450 [TBL] [Abstract][Full Text] [Related]
47. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Genovese MC; Smolen JS; Takeuchi T; Burmester G; Brinker D; Rooney TP; Zhong J; Daojun M; Saifan C; Cardoso A; Issa M; Wu WS; Winthrop KL Lancet Rheumatol; 2020 Jun; 2(6):e347-e357. PubMed ID: 38273598 [TBL] [Abstract][Full Text] [Related]
48. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L; Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593 [TBL] [Abstract][Full Text] [Related]
49. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M; Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398 [TBL] [Abstract][Full Text] [Related]
50. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG; Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037 [TBL] [Abstract][Full Text] [Related]
51. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484 [TBL] [Abstract][Full Text] [Related]
52. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S; Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801 [TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study. Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231 [TBL] [Abstract][Full Text] [Related]
54. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU; Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810 [TBL] [Abstract][Full Text] [Related]
55. Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study. Liu X; Zhou H; Hu Y; Yin J; Li J; Chen W; Huang R; Gong Y; Luo C; Mei H; Ding B; Gu C; Sun H; Leng Y; Ji D; Li Y; Yin H; Shi H; Chen K; Wang J; Fan S; Su W; Yang R Lancet Haematol; 2023 Jun; 10(6):e406-e418. PubMed ID: 37028433 [TBL] [Abstract][Full Text] [Related]
56. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study. Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213 [TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Zakrzewska JM; Palmer J; Morisset V; Giblin GM; Obermann M; Ettlin DA; Cruccu G; Bendtsen L; Estacion M; Derjean D; Waxman SG; Layton G; Gunn K; Tate S; Lancet Neurol; 2017 Apr; 16(4):291-300. PubMed ID: 28216232 [TBL] [Abstract][Full Text] [Related]
58. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236 [TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. van der Heijde D; Song IH; Pangan AL; Deodhar A; van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Everding A; Sui Y; Wang X; Chu AD; Sieper J Lancet; 2019 Dec; 394(10214):2108-2117. PubMed ID: 31732180 [TBL] [Abstract][Full Text] [Related]
60. A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis. Decker RL; Steven Ernest C; Radtke DB; Wang R; Araújo J; Keller SY; Zhang X CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):970-981. PubMed ID: 38532270 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]